Your browser doesn't support javascript.
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic.
Zuliani, Serena; Zampiva, Ilaria; Tregnago, Daniela; Casali, Miriam; Cavaliere, Alessandro; Fumagalli, Arianna; Merler, Sara; Riva, Silvia Teresa; Rossi, Alice; Zacchi, Francesca; Zaninotto, Elisa; Auriemma, Alessandra; Pavarana, Michele; Soldà, Caterina; Benini, Lavinia; Borghesani, Michele; Caldart, Alberto; Casalino, Simona; Gaule, Marina; Kadrija, Dzenete; Mongillo, Marta; Pesoni, Camilla; Biondani, Pamela; Cingarlini, Sara; Fiorio, Elena; Melisi, Davide; Parolin, Veronica; Tondulli, Luca; Belluomini, Lorenzo; Zecchetto, Camilla; Avesani, Barbara; Biasi, Assunta; Bovo, Chiara; Dazzani, Elena; Dodi, Alessandra; Gelmini, Sara; Leta, Luigi Carmine; Lo Cascio, Giuliana; Lombardo, Fiorella; Lucin, Eleonora; Martinelli, Ilaria Asja; Messineo, Luisa; Moscarda, Viola; Pafumi, Sarah; Reni, Anna; Sartori, Giulia; Scaglione, Ilaria Mariangela; Shoval, Yiftach; Sposito, Marco; Tacconelli, Evelina.
  • Zuliani S; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: serena.zuliani@aovr.veneto.it.
  • Zampiva I; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: ilariazampiva@gmail.com.
  • Tregnago D; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: danielatregnago@libero.it.
  • Casali M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: mi.ma.casali@gmail.com.
  • Cavaliere A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: alessandro.cavaliere@studenti.univr.it.
  • Fumagalli A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: fumagalli.arianna@gmail.com.
  • Merler S; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: saramerler@yahoo.it.
  • Riva ST; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: silviateresariva@gmail.com.
  • Rossi A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: ali.red@hotmail.it.
  • Zacchi F; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: francyzacchi@gmail.com.
  • Zaninotto E; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: elisa.zaninotto@gmail.com.
  • Auriemma A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: alessandra.auriemma@aovr.veneto.it.
  • Pavarana M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: michele.pavarana@aovr.veneto.it.
  • Soldà C; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: caterina.solda@aovr.veneto.it.
  • Benini L; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: lavibenini@hotmail.it.
  • Borghesani M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: borghesanimichele@gmail.com.
  • Caldart A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: alberto.caldart@gmail.com.
  • Casalino S; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: simonacasalino@hotmail.it.
  • Gaule M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: marinagaule@gmail.com.
  • Kadrija D; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: dzenete.kadrija@gmail.com.
  • Mongillo M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: marta.mongi9@gmail.com.
  • Pesoni C; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: camilla.pesoni@gmail.com.
  • Biondani P; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: pamela.biondani@aovr.veneto.it.
  • Cingarlini S; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: sara.cingarlini@aovr.veneto.it.
  • Fiorio E; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: elena.fiorio@aovr.veneto.it.
  • Melisi D; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: davide.melisi@univr.it.
  • Parolin V; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: veronica.parolin@aovr.veneto.it.
  • Tondulli L; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: luca.tondulli@aovr.veneto.it.
  • Belluomini L; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: lorenzo.belluomini08@gmail.com.
  • Zecchetto C; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: camilla.zecchetto@gmail.com.
  • Avesani B; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: b.avesani90@gmail.com.
  • Biasi A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: assunta.biasi@aovr.veneto.it.
  • Bovo C; Medical Direction, Verona University Hospital Trust, Verona, Italy. Electronic address: chiara.bovo@aovr.veneto.it.
  • Dazzani E; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: elena.dazzani@aovr.veneto.it.
  • Dodi A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: alessandra.dodi92@gmail.com.
  • Gelmini S; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: sara.gelmini@aovr.veneto.it.
  • Leta LC; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: luigi.c.leta@gmail.com.
  • Lo Cascio G; Microbiology and Virology Unit, Verona University Hospital Trust, Verona, Italy. Electronic address: giuliana.locascio@aovr.veneto.it.
  • Lombardo F; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: fiorella.med@gmail.com.
  • Lucin E; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: eleonora.lucin@gmail.com.
  • Martinelli IA; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: ilariaasjamartinelli88@gmail.com.
  • Messineo L; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: luisa.messineo@hotmail.com.
  • Moscarda V; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: viola.moscarda01@universitadipavia.it.
  • Pafumi S; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: sarahpafumi@gmail.com.
  • Reni A; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: anna.reni9692@gmail.com.
  • Sartori G; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: sartorigmt@gmail.com.
  • Scaglione IM; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: ilariascaglione@tiscali.it.
  • Shoval Y; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: yiftachshoval@gmail.com.
  • Sposito M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: marcosposito91@gmail.com.
  • Tacconelli E; Section of Infectious Diseases, Department of Diagnostic and Public Health, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: evelina.tacconelli@univr.it.
Eur J Cancer ; 135: 159-169, 2020 08.
Article in English | MEDLINE | ID: covidwho-614144
ABSTRACT

BACKGROUND:

On February 23rd, the 1st case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed at the University Hospital Trust of Verona, Italy. On March 13th, the Oncology Section was converted into a 22-inpatient bed coronavirus disease (COVID) Unit, and we reshaped our organisation to face the SARS-CoV-2 epidemic, while maintaining oncological activities.

METHODS:

We tracked down (i) volumes of oncological activities (January 1st - March 31st, 2020 versus the same period of 2019), (ii) patients' and caregivers' perception and (iii) SARS-CoV-2 infection rate in oncology health professionals and SARS-CoV-2 infection-related hospital admissions of "active"' oncological patients.

RESULTS:

As compared with the same trimester in 2019, the overall reduction in total numbers of inpatient admissions, chemotherapy administrations and specialist visits in January-March 2020 was 8%, 6% and 3%, respectively; based on the weekly average of daily accesses, reduction in some of the oncological activities became statistically significant from week 11. The overall acceptance of adopted measures, as measured by targeted questionnaires administered to a sample of 241 outpatients, was high (>70%). Overall, 8 of 85 oncology health professionals tested positive for SARS-CoV-2 infection (all but one employed in the COVID Unit, no hospital admissions and no treatment required); among 471 patients admitted for SARS-CoV-2 infection, 7 had an "active"' oncological disease (2 died of infection-related complications).

CONCLUSIONS:

A slight, but statistically significant reduction in oncology activity was registered during the SARS-CoV-2 epidemic peak in Verona, Italy. Organisational and protective measures adopted appear to have contributed to keep infections in both oncological patients and health professionals to a minimum.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Infection Control / Coronavirus Infections / Pandemics / Betacoronavirus / Medical Oncology / Neoplasms Type of study: Diagnostic study / Observational study / Prognostic study / Qualitative research Limits: Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Eur J Cancer Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Infection Control / Coronavirus Infections / Pandemics / Betacoronavirus / Medical Oncology / Neoplasms Type of study: Diagnostic study / Observational study / Prognostic study / Qualitative research Limits: Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Eur J Cancer Year: 2020 Document Type: Article